Analysts Issue Forecasts for Galapagos NV’s FY2024 Earnings (NASDAQ:GLPG)

Galapagos NV (NASDAQ:GLPG) – Equities research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Galapagos in a research report issued on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the biotechnology company will post earnings per share of $0.08 for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Galapagos’ current full-year earnings is $0.82 per share. Leerink Partnrs also issued estimates for Galapagos’ Q4 2024 earnings at ($0.17) EPS and FY2026 earnings at ($2.06) EPS.

A number of other research analysts have also recently commented on the company. Leerink Partners started coverage on Galapagos in a research report on Monday. They set a “market perform” rating and a $24.00 price target on the stock. Raymond James lowered shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Based on data from MarketBeat, Galapagos has an average rating of “Hold” and a consensus price target of $31.00.

Galapagos Price Performance

Galapagos stock opened at $29.22 on Tuesday. The firm has a 50 day moving average price of $26.64 and a 200-day moving average price of $28.71. Galapagos has a twelve month low of $24.16 and a twelve month high of $42.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP bought a new stake in shares of Galapagos during the 4th quarter worth $5,284,000. Stonepine Capital Management LLC lifted its stake in Galapagos by 23.2% during the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock worth $12,018,000 after purchasing an additional 91,366 shares during the last quarter. DME Capital Management LP boosted its holdings in shares of Galapagos by 46.9% in the 2nd quarter. DME Capital Management LP now owns 234,828 shares of the biotechnology company’s stock worth $5,819,000 after purchasing an additional 75,000 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Galapagos by 3.9% during the 4th quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock valued at $20,131,000 after purchasing an additional 18,552 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Galapagos during the 2nd quarter valued at about $456,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.